中国医学前沿杂志（电子版）2025，Vol.17Issue(6)：14-20,7.DOI:10.12037/YXQY.2025.06-02
恩他卡朋双多巴在帕金森病治疗中的临床价值与应用建议
The clinical value and application recommendations of levodopa/carbidopa/entacapone in the treatment of Parkinson's disease
摘要
Abstract
Levodopa/carbidopa/entacapone(LCE),as a novel combination levodopa formulation,significantly improves symptoms in Parkinson's disease(PD)patients by increasing dopamine concentrations in the brain.LCE has been shown to enhance motor function,daily living activities,and delay disease progression in early-stage PD patients,making it a preferred treatment option for this population.In patients with moderate to advanced PD,LCE significantly prolongs the"on"period,shortens the"off"period,effectively reduces the occurrence of motor complications.Moreover,LCE demonstrates notable therapeutic benefits in improving cognitive function,sleep disorders,and mood disturbances.LCE exhibits good safety and tolerability,with adverse reactions generally mild and manageable.Compared to traditional levodopa/carbidopa regimens,LCE offers a higher therapeutic cost-effectiveness ratio,reducing long-term healthcare costs.Therefore,LCE has broad clinical application prospects.In clinical practice,the dosage should be gradually titrated to ensure patient tolerance and minimize adverse reactions.Additionally,it is recommended to regularly monitor liver,kidney,and cardiovascular functions during treatment to ensure the safety of the therapy.关键词
帕金森病/药物治疗/疗效/安全性Key words
Parkinson's disease/Drug treatment/Efficacy/Safety引用本文复制引用
张典,秦斌,李婷,时晶..恩他卡朋双多巴在帕金森病治疗中的临床价值与应用建议[J].中国医学前沿杂志（电子版）,2025,17(6):14-20,7.基金项目
国家自然科学基金项目(82204921) National Natural Science Foundation of China(82204921) （82204921）
